Roche (ROG) Given a CHF 325 Price Target by Goldman Sachs Group Analysts
Several other brokerages also recently weighed in on ROG. set a CHF 203 price objective on shares of Roche and gave the company a sell rating in a research report on Friday, October 20th. Baader Bank set a CHF 256 price objective on shares of Roche and gave the company a buy rating in a research report on Tuesday, November 21st. Barclays set a CHF 305 price objective on shares of Roche and gave the company a buy rating in a research report on Wednesday, December 27th. Berenberg Bank set a CHF 260 price target on shares of Roche and gave the stock a neutral rating in a research report on Tuesday, October 24th. Finally, DZ Bank set a CHF 270 price target on shares of Roche and gave the stock a buy rating in a research report on Friday, February 2nd. Four analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and an average target price of CHF 257.20.
Shares of Roche (VTX:ROG) opened at CHF 215.95 on Wednesday. The firm has a market cap of $185,900.00 and a PE ratio of 21.51. Roche has a 52-week low of CHF 214.30 and a 52-week high of CHF 273.
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.